OVERVIEW

Substance Use in Pregnancy | Mishka Terplan, MD, MPH is organized by California Society of Addiction Medicine (CSAM).

Course opens: 09/22/2016
Course expires: 08/24/2019

Target Audience:
• Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice.
• Primary care clinicians who want to get a better understanding of addiction and manage patients with addictions in their practice.
• Public health officials who want an understanding of the current state of addiction treatment.
• Non-physicians who are involved in the treatment of addiction.

Available Credit:
• 1 AMA PRA Category 1 Credit™
• 1.00 Attendance

MOC:
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 1 AMA/PRA Category 1 Credits™ for completing the Review Course.

Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors.

Course Overview:
This lecture reviews:
• History of opioid epidemics in women
• Pregnant women and stigma
• Epidemiology of drug use in pregnancy
• Outcomes of perinatal drug exposure (alcohol, opioids, tobacco)
• Treatment of addiction in pregnancy (opioids)
• Neonatal abstinence syndrome and newborn reporting

Learning Objectives:
As a result of participating in this lecture learners should have a working knowledge of the following topics, essential to competency in addiction medicine and identify areas where more study may be needed:

• Epidemiology of alcoholism and addiction in women (including tobacco)
• Overview of screening tools designed for this population
• Overview of office-based brief interventions with pregnant patients and new moms,
• Changes in drug dosing/volume of distribution or metabolism during pregnancy
• Effects on the fetus of the mode of maternal drug use (oral, intravenous, intranasal, inhalation, IM) and type of drug used
• Obstetrical complications and pregnancy-related disorders and complications involving alcohol, tobacco, and drugs (preterm, SABO, ID, nutrition, routine medical care etc)
• Routes of fetal/neonatal exposure to alcohol, tobacco, and drugs (placenta/nursing/second hand), fetal/perinatal effects of such exposure and if there are peaks of vulnerability (neurological/physical/ cognitive)
• Pharmacologic and non-pharmacologic intervention for neonatal intoxication and withdrawal for opioids and sedatives
• Clinical management of the alcoholic/addicted/smoking pregnant patient (evidence-based, pharmacologic, residential, etc),
• Include any comments on treatment modalities that work better or worse on this population or are contraindicated and why
• FAS, cognitive and behavioral diagnoses secondary to in-utero alcohol and drug exposure.
• Management of adverse impact of alcohol on the fetus,
• Ethical/legal/liability considerations.
• Briefly describe the design, outcome, limitations and clinical implications of the MOTHERS Study.